FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109080255> ?p ?o ?g. }

• W2109080255 endingPage "3083" @default.
• W2109080255 startingPage "3076" @default.
• W2109080255 abstract "Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non–small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations. Resistance emerges after 9 to 12 months, primarily mediated by the T790M resistance mutation. We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M. Patients and Methods Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment. Those with ≥ 12 weeks of prior TKI therapy were placed in arm A if they were EGFR mutation positive or arm B if they were wild-type. Arm C included TKI-naïve patients with adenocarcinoma and light smoking histories (≤ 20 pack-years). All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea. The primary end point was objective response rate (RR). Results One-hundred sixty-seven patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C. Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose reduction. The RR was 3% in arm A and zero in arms B and C. No patients with known T790M responded. Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 weeks. Conclusion Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naïve patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation. Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents." @default.
• W2109080255 created "2016-06-24" @default.
• W2109080255 creator A5003723404 @default.
• W2109080255 creator A5005700483 @default.
• W2109080255 creator A5013749269 @default.
• W2109080255 creator A5019034689 @default.
• W2109080255 creator A5023794502 @default.
• W2109080255 creator A5030914311 @default.
• W2109080255 creator A5035120516 @default.
• W2109080255 creator A5041247232 @default.
• W2109080255 creator A5044795397 @default.
• W2109080255 creator A5056830887 @default.
• W2109080255 creator A5063427877 @default.
• W2109080255 creator A5075333926 @default.
• W2109080255 creator A5089572773 @default.
• W2109080255 date "2010-06-20" @default.
• W2109080255 modified "2023-10-13" @default.
• W2109080255 title "Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer" @default.
• W2109080255 cites W1967394241 @default.
• W2109080255 cites W1970476748 @default.
• W2109080255 cites W1988442083 @default.
• W2109080255 cites W1990097438 @default.
• W2109080255 cites W1993604070 @default.
• W2109080255 cites W2002937040 @default.
• W2109080255 cites W2003984225 @default.
• W2109080255 cites W2005216767 @default.
• W2109080255 cites W2009481811 @default.
• W2109080255 cites W2012784647 @default.
• W2109080255 cites W2023532383 @default.
• W2109080255 cites W2043696829 @default.
• W2109080255 cites W2050156776 @default.
• W2109080255 cites W2068244265 @default.
• W2109080255 cites W2070011883 @default.
• W2109080255 cites W2076668534 @default.
• W2109080255 cites W2093922887 @default.
• W2109080255 cites W2095618958 @default.
• W2109080255 cites W2101329867 @default.
• W2109080255 cites W2107304950 @default.
• W2109080255 cites W2110444464 @default.
• W2109080255 cites W2112602910 @default.
• W2109080255 cites W2114195503 @default.
• W2109080255 cites W2121389354 @default.
• W2109080255 cites W2122553809 @default.
• W2109080255 cites W2138297714 @default.
• W2109080255 cites W2139236349 @default.
• W2109080255 cites W2139248078 @default.
• W2109080255 cites W2139343412 @default.
• W2109080255 cites W2139799027 @default.
• W2109080255 cites W2140775102 @default.
• W2109080255 cites W2149952977 @default.
• W2109080255 cites W2154246971 @default.
• W2109080255 cites W2161821474 @default.
• W2109080255 cites W2163885776 @default.
• W2109080255 cites W2166084034 @default.
• W2109080255 cites W2168554121 @default.
• W2109080255 cites W2168841302 @default.
• W2109080255 cites W2169816570 @default.
• W2109080255 cites W2273115456 @default.
• W2109080255 cites W2298507739 @default.
• W2109080255 cites W2600193304 @default.
• W2109080255 doi "https://doi.org/10.1200/jco.2009.27.9414" @default.
• W2109080255 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20479403" @default.
• W2109080255 hasPublicationYear "2010" @default.
• W2109080255 type Work @default.
• W2109080255 sameAs 2109080255 @default.
• W2109080255 citedByCount "378" @default.
• W2109080255 countsByYear W21090802552012 @default.
• W2109080255 countsByYear W21090802552013 @default.
• W2109080255 countsByYear W21090802552014 @default.
• W2109080255 countsByYear W21090802552015 @default.
• W2109080255 countsByYear W21090802552016 @default.
• W2109080255 countsByYear W21090802552017 @default.
• W2109080255 countsByYear W21090802552018 @default.
• W2109080255 countsByYear W21090802552019 @default.
• W2109080255 countsByYear W21090802552020 @default.
• W2109080255 countsByYear W21090802552021 @default.
• W2109080255 countsByYear W21090802552022 @default.
• W2109080255 countsByYear W21090802552023 @default.
• W2109080255 crossrefType "journal-article" @default.
• W2109080255 hasAuthorship W2109080255A5003723404 @default.
• W2109080255 hasAuthorship W2109080255A5005700483 @default.
• W2109080255 hasAuthorship W2109080255A5013749269 @default.
• W2109080255 hasAuthorship W2109080255A5019034689 @default.
• W2109080255 hasAuthorship W2109080255A5023794502 @default.
• W2109080255 hasAuthorship W2109080255A5030914311 @default.
• W2109080255 hasAuthorship W2109080255A5035120516 @default.
• W2109080255 hasAuthorship W2109080255A5041247232 @default.
• W2109080255 hasAuthorship W2109080255A5044795397 @default.
• W2109080255 hasAuthorship W2109080255A5056830887 @default.
• W2109080255 hasAuthorship W2109080255A5063427877 @default.
• W2109080255 hasAuthorship W2109080255A5075333926 @default.
• W2109080255 hasAuthorship W2109080255A5089572773 @default.
• W2109080255 hasBestOaLocation W21090802551 @default.
• W2109080255 hasConcept C121608353 @default.
• W2109080255 hasConcept C126322002 @default.
• W2109080255 hasConcept C143998085 @default.
• W2109080255 hasConcept C2776256026 @default.
• W2109080255 hasConcept C2777930144 @default.

• next